QUALCOMM, Inc. (NASDAQ:QCOM) has announced that it is partnering with Roche to enter the medical domain. Both the companies will launch diagnostics tools and systems for effective patient caretaking, tracking of chronic disease patients and connected medical domains. QUALCOMM, Inc. (NASDAQ:QCOM) has a subsidiary named Qualcomm Life, which will deal this project.
QUALCOMM, Inc. (NASDAQ:QCOM)’s 2Net platform is the key in this project. 2Net platform is a secure, wireless technology which captures data and information from medical devices, like anticoagulation meters, trackers to Cloud. Roche’s Cloud will be deployed at the back end for data analysis. All the data will be captured from a patient’s specific medical devices using QUALCOMM, Inc. (NASDAQ:QCOM) technology and it will be coupled up with Cloud data attributes for further refinement.
A joint statement by QUALCOMM, Inc. (NASDAQ:QCOM) and Roche was issued a PR News Wire. With the help of Qualcomm’s remote chronic patient management system, doctors will be able to handle their patients, information remotely, with the minimal chances of error. It will also allow the patients to have more control over their data and information. Connecting devices asynchronously both at patient and doctors end can help manage the medical costs dramatically.
Roche excels in point-of-care medical solutions. The source said that the perfect mixture of QUALCOMM, Inc. (NASDAQ:QCOM)’s connected technology and point of care technology will help patients and doctors control data. QUALCOMM, Inc. (NASDAQ:QCOM) said that the new technology will also facilitate nurses and caretakers in managing their patients efficiently, with less effort.
Ken Fisher’s Fisher Asset Management had the biggest position in QUALCOMM, Inc. (NASDAQ:QCOM), worth close to $695.5 million.